Arizona Tribune - Lifeloc Reports First Quarter 2025 Results

First Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.277 million resulting in a quarterly net loss of $(293) thousand, or $(0.11) per diluted share. These results compare to net revenue of $2.153 million and quarterly net loss of ($284) thousand, or ($0.12) per diluted share in the first quarter of 2024. Revenue grew by $124 thousand or 6% versus the first quarter last year. Gross margin in the first quarter improved to 39.9% versus 38.8% last year, due primarily to increased pricing and better volumes. Research and Development investment remains high at more than 20% of revenue, primarily for SpinDx development, contributing significantly to the current period loss.

We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that are driving market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. Sales of our newer L-series devices are mostly incremental to our installed base of FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. We continue to evolve the capability and certifications of these units to add more value and gain market share. Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and contributes to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.

We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are therefore focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace test sites to achieve a rapid and quantitative measure for a panel of drugs of abuse. Our SpinDx product enables rapid, on-site, and cost-effective drug testing using a centrifugal disk platform capable of detecting trace levels of drugs from small samples. Despite initial delays due to the pandemic, we have advanced the technology and filed our first utility patent application in 2024 for improvements to the system. SpinDx™ offers a unique advantage over competitors by isolating psychoactive delta-9-THC from its inactive metabolites, enabling more accurate impairment detection-especially critical for marijuana testing where competitive devices may yield false positives from non-impairing compounds. Beta testing with human subjects is set to begin in partnership with Anschutz Medical Center in Colorado, with commercial launch expected in 2026. We plan to launch the product in stages, beginning with a saliva-based system, followed by blood and breath sample capabilities, using our LX9 breathalyzer to produce a roadside marijuana breathalyzer system.

"Rapid drug testing is our biggest growth opportunity, and we believe that SpinDx will play an important role in addressing this unmet market need," commented Dr. Wayne Willkomm, President and CEO. "We have chosen to prioritize long term value creation over short term profitability to fund this opportunity. We anticipate continued high research and development expenses in this final push toward commercialization and are excited to begin to show our customers this developmental model."

Additionally, in alignment with the evolving structure of the OTC Markets, Lifeloc has completed its application for the OTCID, which will be the new market tier of the OTC Markets, effective July 1, 2025. OTCID is the replacement for fully reporting companies from the OTC Pink Current Market, which will cease July 1, 2025. We believe the new OTCID standards will create greater market confidence than the OTC Pink and allow a more liquid marketplace for our shareholders.

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.

Easycal® and Phoenix^® are registered trademarks of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500

SOURCE: Lifeloc Technologies, Inc.

View the original press release on ACCESS Newswire

A.O.Scott--AT